MedPath

Omron's AI-Powered Atrial Fibrillation Detection Receives FDA Approval

• Omron Healthcare secured FDA de novo authorization for its AI-powered atrial fibrillation (AFib) detection technology integrated into home blood pressure monitors. • The IntelliSense AFib algorithm analyzes pressure pulse waves during blood pressure measurements, demonstrating 95% sensitivity and 98% specificity in detecting AFib. • This innovation marks the first instance of machine learning being incorporated into home blood pressure monitors for AFib detection, addressing a significant unmet need. • Omron plans to launch the new blood pressure monitors in the U.S. market in early 2025, aiming to empower patients in proactive health management.

Omron Healthcare has received de novo authorization from the U.S. Food and Drug Administration (FDA) for its new home blood pressure monitors equipped with AI-powered atrial fibrillation (AFib) detection technology. This marks a significant advancement in digital health, addressing the growing AFib epidemic through the integration of advanced AI into routine blood pressure monitoring.
The FDA approval underscores Omron’s commitment to delivering medical-grade accuracy via its IntelliSense AFib algorithm. This algorithm analyzes the pressure pulse wave during blood pressure measurements to detect AFib with high precision. According to Omron, AFib is the most common heart arrhythmia and significantly elevates the risk of stroke, heart failure, and other severe health conditions if left untreated.
The FDA’s de novo classification pathway highlights the novelty of this technology, making it the first of its kind to incorporate machine learning into home blood pressure monitors for AFib detection. Industry experts view this as a crucial step forward in combating a condition affecting millions of undiagnosed Americans.

Clinical Validation of IntelliSense AFib Technology

A study published in the October 2024 issue of the Heart Rhythm Journal reported that Omron’s IntelliSense AFib technology demonstrated a sensitivity of 95% and a specificity of 98% for AFib detection. These results validate the effectiveness of this innovation in accurately identifying individuals at risk.

Market Launch and Future Implications

Omron plans to launch its new blood pressure monitors with IntelliSense AFib in the U.S. market in early 2025. This launch aligns with the company’s focus on empowering patients to proactively manage their health, utilizing AI-driven technologies to bridge the gap between traditional and digital healthcare. The integration of AI into home-based monitoring devices represents a shift towards more accessible and proactive healthcare solutions, potentially reducing the burden on healthcare systems and improving patient outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

HeartBeam Submits FDA Application for 12-Lead ECG Synthesis Software

HeartBeam has submitted a 510(k) application to the FDA for its 12-lead ECG synthesis software, designed to assess various cardiac rhythms and arrhythmias.
The submission is supported by data from the VALID-ECG pivotal study, involving 198 patients across five clinical sites, demonstrating clinical equivalence to standard ECGs.

MVITRO's ORTIV Receives FDA Clearance for Needle-Free Blood Sampling

MVITRO's ORTIV, a laser-based device for painless blood sampling and glucose monitoring, has secured FDA 510(k) clearance, marking a significant advancement in diabetes management.
ORTIV utilizes micro-lasers to minimize skin damage and eliminate infection risks, offering real-time glucose readings via a dedicated app, addressing the stress of traditional blood sampling.

FDA Approves AI Tool icobrain aria for Detecting ARIA in Alzheimer's Immunotherapy Patients

The FDA has approved icobrain aria, an AI-driven software, to assist in detecting ARIA (Amyloid-Related Imaging Abnormalities) in MRI scans of patients undergoing amyloid immunotherapy.
Clinical studies showed that radiologists using icobrain aria improved their sensitivity in detecting ARIA-E from 71% to 87% and ARIA-H from 69% to 79%.

FDA Approves Novel Therapies for Frostbite, Food Allergies, and Synovial Sarcoma in 2024

The FDA approved Aurlumyn (iloprost) in February 2024, the first-ever treatment for severe frostbite, significantly reducing the risk of amputation in affected patients.
Omalizumab (Xolair) received FDA approval in February 2024 to reduce allergic reactions following accidental food exposure, benefiting individuals with life-threatening food allergies.

FDA Approves Medtronic's Affera System for Atrial Fibrillation Ablation

The FDA has approved Medtronic's Affera system, an all-in-one mapping and ablation solution, for treating atrial fibrillation (AFib).
The approval was based on the SPHERE PER-AF trial, which demonstrated the Affera system's non-inferiority to standard care in persistent AFib patients.

Siemens Healthineers' Blood Test Receives FDA Clearance for Predicting Heart Attack Risk

Siemens Healthineers' Atellica IM high-sensitivity troponin I (TnIH) blood test secures FDA clearance for predicting major cardiac events and death risk up to one year in advance.
The Atellica IM TnIH test measures cardiac troponin I, a biomarker indicating heart muscle injury, and is already used in many U.S. hospitals.

XYRA Receives FDA Guidance on Budiodarone Labeling for Atrial Fibrillation Management with Wearable Monitoring

XYRA has secured FDA guidance for incorporating wearable atrial fibrillation (AF) monitoring devices into the drug label for budiodarone, a potential treatment for non-permanent AF.
The FDA's guidance specifies directions for use to control AF symptoms and reduce stroke risk by eliminating long episodes of AF (LEAF) exceeding 5 hours, as demonstrated in Phase 2 trials.

AccurKardia and iCardio.ai Advance AI-Powered Cardiac Screening with FDA Designations

AccurKardia received FDA Breakthrough Device designation for its AI-driven ECG software designed to detect aortic valve stenosis (AVS) using existing ECG data.
iCardio.ai obtained FDA 510(k) clearance for its AI software, EchoMeasure, which automates echocardiographic interpretation and streamlines imaging workflows.

Nevro's AI-Powered Spinal Cord Stimulation System, HFX iQ with AdaptivAI, Receives FDA Approval

Nevro's HFX iQ with AdaptivAI, an AI-driven spinal cord stimulation system, has gained FDA approval for chronic pain management.
HFX AdaptivAI leverages AI and patient data to personalize pain relief, optimizing therapy and potentially reducing device charging frequency.

U.S. FDA Grants Priority Review for Elafibranor, a Potential New Treatment for Primary Biliary Cholangitis

The U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of elafibranor, a potential novel second-line treatment for primary biliary cholangitis (PBC), a rare cholestatic liver disease. The European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have also validated the Marketing Authorization Application (MAA) for review. The target FDA PDUFA date is set for June 10, 2024.

Reference News

[1]
FDA approves Omron AI-powered AFib detection in blood pressure monitors
medicaldevice-network.com · Nov 20, 2024

Omron Healthcare received FDA de novo authorization in Oct 2024 for home blood pressure monitors with AI-powered AFib de...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy